Sex Differences in Inmates: Anger, Sensitivity to Provocation and Family History of Imprisonment

Author(s):  
Marta Bodecka-Zych ◽  
Anna Zajenkowska ◽  
Mary Bower Russa

Little research has explored the role of aggression, anger, and family history of incarceration as they relate to female offenders. The current study aimed to address this gap in the literature by investigating these possible risk factors for incarceration among both men and women. The survey involved 123 (61 female and 62 male) prisoners convicted for violent crimes and a comparison group of 118 (60 female and 58 male) adults from the community. We found that women (convicted and non-convicted) were more sensitive to provocation than men, while community adults showed higher levels of trait anger than prisoners. Detainees were more likely than community adults to have a relative in prison. Although male and female inmates were equally likely to have a relative in prison, they differed in their relation to the imprisoned relative. Male and female prisoners showed increased risk for incarceration of same sex, first degree relatives (father and brothers for men, and mothers for women). These results may contribute to improved understanding of incarcerated populations. As such, this represents a critical first step in creating recovery programs that are more gender appropriate.

2008 ◽  
Vol 23 (7) ◽  
pp. 527-531 ◽  
Author(s):  
M. Walshe ◽  
L. Rifkin ◽  
M. Rooney ◽  
E. Healy ◽  
C. Nosarti ◽  
...  

AbstractObjectiveTo investigate whether young adults born very preterm (VPT) (<33 weeks) are at increased risk for psychiatric illness in adulthood and whether a family history of psychiatric disorder further increases this risk.MethodsWe assessed 169 VPT and 101 term born individuals using the Clinical Interview Schedule – Revised.ResultsYoung adults born VPT had an increased risk for psychiatric disorder compared to controls (OR = 3.1, 95% CI = 1.1–8.6, p = 0.03). Those born VPT who had a history of psychiatric disorder in a first-degree relative, had an increase in risk for psychiatric disorder compared to those born VPT without a family history (OR = 5.2, 95% CI = 1.8–14.9, p = 0.002).ConclusionIndividuals born VPT are at increased risk of psychiatric illness in young adulthood compared to controls. In addition, a family history of psychiatric disorder in a first-degree relative may leave young adults born VPT particularly vulnerable to psychiatric illness.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1777-1777
Author(s):  
Eva Domingo-Domènech ◽  
Yolanda Benavente ◽  
Carlos Montalbán ◽  
Ramon Bosch ◽  
Josep Gumà ◽  
...  

Abstract Background and aims: Family history of cancer in lymphoma patients has largely been described. On the other hand, genetic susceptibility associated to lymphoma risk is being investigated at the present time. However, single nucleotide polymorphisms (SNPs) associated to the entity among those reporting family history of cancer have yet not been identified. In a previous study of our group, we identified that the probability of having a first-degree relative with cancer was significantly higher among the patients with lymphoid neoplasm than among the control subjects (43% vs 35%, p&lt;0.05). When analysing by lymphoma subtypes, B-cell lymphoma, chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM) patients were significantly more likely to report a first-degree relative with any cancer, with a risk increase ranging from 1.4 up to 2.1 among CLL patients. Thus, a 2-to 4-fold increased risk of lymphoma has been identified in patients with a family history of hematologic disease or lymphoma in first-degree relatives, with CLL, MM and Hodgkin’s lymphoma (HL) being the three entities more consistently reported. The purpose of this study was to evaluate the role of genetic variants of several polymorphisms in the risk of developing a lymphoid neoplasm among subjects with family history of cancer in the case-control study Epilymph. Material and methods: Newly diagnosed cases of lymphoma were recruited between 1998–2002 in 4 Spanish centers. Controls were hospitalized patients matched to the cases by age, gender and study center. Personal interviews were conducted in order to collect data on demographics, environmental exposure, medical and family history, including cancer. The site of cancer, age at diagnosis, and status of any affected relatives with cancer were requested. In this analysis, we only included those subjects who reported a family history of cancer. 72 SNPs in 47 genes were included in the analysis. DNA of 503 cases and 569 controls were genotyped using the TaqmanTM platform. Odds Ratios (OR) and 95% confidence intervals (CI) for the association of the variants with the risk of lymphoma were calculated using unconditional logistic regression analysis, under the log additive inheritance model. Results: Family history of cancer was reported by 421 subjects (196 controls and 225 cases, p-value=0.001). Among those, 41 had an hematological origin. The two SNP genotyped in IL8RB gene were associated to an increase in risk of lymphoma for every extra variant allele (IL8RB +1235C&gt;T OR=1.68, 95%CI=1.25–2.27 and IL8RB -1010A&gt;G OR=1.59, 95%CI=1.17–2.17). The OR associated to an additional variant allele of Ggh IVS7-3001 polymorphism was 1.82 (95%CI=1.06–3.14). IL-1082 A&gt;G was observed to decrease the risk of lymphoma (OR=0.72, 95%CI=0.54–0.96).Restricting the analysis to those with a familial cancer of hematological origin under a log-additive inheritance model, a statistical increase in the risk was found for every extra variant allele MTHFR +429A&gt;C in the genotype (OR=21.52, 95%CI=2.42–191.08), whereas presenting at least one variant allele of IL10 -1082 A&gt;G decreased the risk of lymphoma (OR=0.05, 95%CI=0.01–0.38). In order to evaluate the association between SNPs and lymphoma subtypes in subjects with family history of cancer, we explored the relation between all statistically significant SNPs reported above and non-Hodgkin lymphomas (NHL), Chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL). We observe that the association of SNPs and all lymphoma is similar after stratifying by subtypes, although these results are based on few subjects. Interestingly, those SNPs related to low risk of lymphoma, were observed to have the lowest risk among HL cases (IL10 -1082 A&gt;G OR=0.28, 95%CI=0.09– 0.82), whereas HL and MM seems to be at higher risk for those SNPs related to increased risk of lymphoma (IL8RB+1235 OR=2.29, 95%CI=1.29–4.05 and IL8RB-1010 OR=2.45, 95%CI=1.33–4.51 for MM and Ggh IVS7-3001 OR=5.47, 95%CI=1.33–22.52 for HL). Conclusions: These results suggest a potential role of IL8RB, GGH IVS7 and IL10 SNPs in the risk of lymphoid neoplasms among subjects with family history of cancer. HL and MM seem to be those entities in which these associations appear to be stronger, although the number of cases included is small.


2001 ◽  
Vol 120 (5) ◽  
pp. A442-A442
Author(s):  
P TSIBOURIS ◽  
M HENDRICKSE ◽  
P ISAACS

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1378-P
Author(s):  
JANAKI D. VAKHARIA ◽  
SUNGEETA AGRAWAL ◽  
JANINE BACIC ◽  
LISA S. TOPOR

2020 ◽  
Vol 210 ◽  
pp. 107955
Author(s):  
Alexander S. Weigard ◽  
Jillian E. Hardee ◽  
Robert A. Zucker ◽  
Mary M. Heitzeg ◽  
Adriene M. Beltz

2021 ◽  
Author(s):  
Arthur Blouin

Abstract Can divide-and-rule colonial policy be responsible for contemporary ethnic tension? This paper empirically investigates the role of a divisive and extractive colonial policy on Hutu-Tutsi discord in Rwanda and Burundi. It shows that Hutu with a family history of subjugation to forced labour by Tutsi chiefs are less trusting of Tutsi today and less willing to partner with Tutsi for a cooperative task. This may have implications for agriculture insurance agreements since Hutu are more agrarian and Tutsi are more pastoral. Indeed, Hutu with a forced labour family history make fewer inter-household insurance agreements and are more likely to experience default.


2021 ◽  
Vol 9 (1) ◽  
pp. e001948
Author(s):  
Marion Denos ◽  
Xiao-Mei Mai ◽  
Bjørn Olav Åsvold ◽  
Elin Pettersen Sørgjerd ◽  
Yue Chen ◽  
...  

IntroductionWe sought to investigate the relationship between serum 25-hydroxyvitamin D (25(OH)D) level and the risk of type 2 diabetes mellitus (T2DM) in adults who participated in the Trøndelag Health Study (HUNT), and the possible effect modification by family history and genetic predisposition.Research design and methodsThis prospective study included 3574 diabetes-free adults at baseline who participated in the HUNT2 (1995–1997) and HUNT3 (2006–2008) surveys. Serum 25(OH)D levels were determined at baseline and classified as <50 and ≥50 nmol/L. Family history of diabetes was defined as self-reported diabetes among parents and siblings. A Polygenic Risk Score (PRS) for T2DM based on 166 single-nucleotide polymorphisms was generated. Incident T2DM was defined by self-report and/or non-fasting glucose levels greater than 11 mmol/L and serum glutamic acid decarboxylase antibody level of <0.08 antibody index at the follow-up. Multivariable logistic regression models were applied to calculate adjusted ORs with 95% CIs. Effect modification by family history or PRS was assessed by likelihood ratio test (LRT).ResultsOver 11 years of follow-up, 92 (2.6%) participants developed T2DM. A higher risk of incident T2DM was observed in participants with serum 25(OH)D level of<50 nmol/L compared with those of ≥50 nmol/L (OR 1.72, 95% CI 1.03 to 2.86). Level of 25(OH)D<50 nmol/L was associated with an increased risk of T2DM in adults without family history of diabetes (OR 3.87, 95% CI 1.62 to 9.24) but not in those with a family history (OR 0.72, 95% CI 0.32 to 1.62, p value for LRT=0.003). There was no effect modification by PRS (p value for LRT>0.23).ConclusionSerum 25(OH)D<50 nmol/L was associated with an increased risk of T2DM in Norwegian adults. The inverse association was modified by family history of diabetes but not by genetic predisposition to T2DM.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Vanni Valeria Stella ◽  
Villanacci Roberta ◽  
Salmeri Noemi ◽  
Papaleo Enrico ◽  
Delprato Diana ◽  
...  

AbstractPathogenesis of endometriosis is still unclear and a role of both innate and adaptive immune system has been postulated. Some recent findings have revealed an increased risk to have concomitant autoimmune disease in women with endometriosis, but no study so far has investigated whether this association could affect endometriosis severity and stage. We retrospectively reviewed medical patients’ notes of women with a confirmed diagnosis of endometriosis who referred to our endometriosis outpatient clinic between January 2015 and December 2019. Cases (endometriosis and an autoimmune disease) were matched in a 1:3 ratio by age and study period with controls (endometriosis without history of autoimmunity). At univariate logistic analysis, concomitant autoimmunity (OR 2.63, 95% CI 1.64–4.21, p < 0.001) and the number of laparoscopic procedures performed (OR 2.81, 95% CI 1.45–5.43, p = 0.002) emerged as factors significantly associated with the likelihood of stage IV endometriosis. In the multivariate logistic regression model, concomitant autoimmunity remained a significant predictor of stage IV endometriosis (OR 2.54, 95% CI 1.57–4.10, p = 0.004), whereas the association between the number of laparoscopic procedures performed and stage IV endometriosis was found to be of borderline-significance (OR 2.70, 95% 1.37–5.30, p = 0.050). Our findings suggest that endometriosis is more severe in patients who are also affected by autoimmune disturbances after controlling for relevant confounders.


2021 ◽  
Author(s):  
Gema Ariceta ◽  
Fadi Fakhouri ◽  
Lisa Sartz ◽  
Benjamin Miller ◽  
Vasilis Nikolaou ◽  
...  

ABSTRACT Background Eculizumab modifies the course of disease in patients with atypical hemolytic uremic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited. Methods Patients enrolled in the Global aHUS Registry who received ≥1 month of eculizumab before discontinuing, demonstrated hematologic or renal response prior to discontinuation and had ≥6 months of follow-up were analyzed. The primary endpoint was the proportion of patients suffering thrombotic microangiopathy (TMA) recurrence after eculizumab discontinuation. Additional endpoints included: eGFR changes following eculizumab discontinuation to last available follow-up; number of TMA recurrences; time to TMA recurrence; proportion of patients restarting eculizumab; and changes in renal function. Results We analyzed 151 patients with clinically diagnosed aHUS who had evidence of hematologic or renal response to eculizumab, before discontinuing. Thirty-three (22%) experienced a TMA recurrence. Univariate analysis revealed that patients with an increased risk of TMA recurrence after discontinuing eculizumab were those with a history of extrarenal manifestations prior to initiating eculizumab, pathogenic variants, or a family history of aHUS. Multivariate analysis showed an increased risk of TMA recurrence in patients with pathogenic variants and a family history of aHUS. Twelve (8%) patients progressed to end-stage renal disease after eculizumab discontinuation; 7 (5%) patients eventually received a kidney transplant. Forty (27%) patients experienced an extrarenal manifestation of aHUS after eculizumab discontinuation. Conclusions Eculizumab discontinuation in patients with aHUS is not without risk, potentially leading to TMA recurrence and renal failure. A thorough assessment of risk factors prior to the decision to discontinue eculizumab is essential.


2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Victoria Hale ◽  
Maren Weischer ◽  
Jong Y. Park

Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer.CHEK2plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current knowledge of the role of a genetic variant, 1100delC, ofCHEK2on prostate cancer risk and discuss the implication for potential translation of this knowledge into clinical practice. Currently, twelve articles that discussedCHEK2∗1100delC and its association with prostate cancer were identified. Of the twelve prostate cancer studies, five studies had independent data to draw conclusive evidence from. The pooled results of OR and 95% CI were 1.98 (1.23–3.18) for unselected cases and 3.39 (1.78–6.47) for familial cases, indicating thatCHEK2∗1100delC mutation is associated with increased risk of prostate cancer. Screening for CHEK2∗1100delC should be considered in men with a familial history of prostate cancer.


Sign in / Sign up

Export Citation Format

Share Document